<DOC>
	<DOCNO>NCT01678209</DOCNO>
	<brief_summary>The grow number medication use treat attention-deficit/hyperactivity disorder ( ADHD ) raise important question whether different medication similar different therapeutic mechanism action . We recently show stimulant methylphenidate ( MPH ) non-stimulant atomoxetine ( ATX ) produce clinical improvement via common mechanism motor cortex , distinct action frontostriatal midline cingulate-precuneus region . These exciting finding offer window common unique neurophysiological mechanism response stimulant non-stimulant treatment . However , interpretation clinical utility result would greatly enhance in-depth investigation impact two treatment relevant neural network , analysis evaluate whether improvement achieve via normalization adaptive change brain function .</brief_summary>
	<brief_title>Imaging Stimulant Non Stimulant Treatments ADHD : A Network Based Approach</brief_title>
	<detailed_description>The specific aim project use functional magnetic resonance imaging ( fMRI ) determine significance activation change treatment related clinical improvement , impact treatment neural connectivity within anti-correlated frontostriatal 'task-positive ' circuit cingulate-precuneus 'task-negative ' network . Our central hypothesis clinical improvement associate : ( ) normalization reduce connectivity region within 'task-positive ' network , resultant increase inhibition motor cortex , ( ii ) normalization low task-related connectivity region within task-negative network MPH 'task-positive ' network ATX . This research propose test model posit neurophysiological basis mechanism response stimulant non-stimulant medication , fit long term objective able match treatment individual patient . Testing model require large sample youth scan use fMRI treatment , match healthy control also scan twice . We use innovative network-based approach study effect treatment , build result current fMRI treatment study , incorporate new theoretical approach understand ADHD treatment .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<criteria>General inclusion criterion subject ADHD healthy control : age 717 year ; Wechsler Intelligence Scale Children ( WISC ) score ≥ 75 ; inform consent assent study participation . Specific inclusion criterion youth ADHD : diagnosis ADHD , subtype , determine Kiddie Schedule Affective Disorders Schizophrenia SchoolAged ChildrenPresent Lifetime Versions ( KSADSPL ) ; ADHD Rating ScaleIVParent Version : Investigator Administered ( ADHDRSIV ) total score ≥ 1.5 SD age gender mean subtype Clinical Global ImpressionsADHDSeverity ( CGIS ) score &gt; 4 ; ADHD must primary diagnosis focus treatment , treatment offer study must contraindicate comorbid disorder . General exclusion criterion : history head injury loss consciousness CNS disease likely affect brain function ; diagnosis autism pervasive developmental , psychotic , major mood , Tourette 's disorder ; alcohol drug abuse past 3 month positive urinary toxic screen initial evaluation ; use psychotropic medication within 2 week study ( 8 week fluoxetine ) ; preexist medical psychological condition precludes scanner ( e.g. , claustrophobia , morbid obesity ) ; metal body precludes scan ( e.g. , brace , metal plate ) ; positive urine pregnancy test . Specific exclusion criterion treatment trial include : previous unsuccessful trial MPH ATX adequately dose ( ≥ 1 mg/kg MPH 1.0 mg/kg ATX ) adequate duration ( ≥ 4 week ) ; abnormal finding physical exam , vital sign pulse blood pressure &gt; 95 % age gender mean ; inability swallow capsule ; weight &lt; 20 kg &gt; 85 kg . Specific exclusion criterion control youth include : past history current diagnosis psychiatric disorder , determine KSADSPL interview ; ADHDRSIV CBCL score symptom domain ≤ 1 SD age gender mean .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>Stimulant</keyword>
	<keyword>Non-stimulant</keyword>
	<keyword>Drug</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>Atomoxetine</keyword>
	<keyword>Strattera</keyword>
	<keyword>Concerta</keyword>
	<keyword>MACRO</keyword>
	<keyword>Medication</keyword>
	<keyword>Treatment</keyword>
	<keyword>Youth</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Functional Magnetic Resonance Imaging</keyword>
	<keyword>Brain scan</keyword>
	<keyword>Imaging</keyword>
	<keyword>Response inhibition</keyword>
	<keyword>Inattentive</keyword>
	<keyword>Hyperactive</keyword>
	<keyword>Combined</keyword>
	<keyword>Medication Treatment</keyword>
	<keyword>Brain Imaging</keyword>
</DOC>